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Abstract 27 
Pyrethroid resistance in malaria vector, An. funestus is increasingly reported across Africa, 28 
threatening the sustainability of pyrethroid-based control interventions including long lasting 29 
insecticidal Nets (LLINs). Managing this problem requires understanding of the molecular 30 
basis of the resistance from different regions of the continent, to establish whether it is being 31 
driven by a single or independent selective events. Here, using a genome-wide transcription 32 
profiling of pyrethroid resistant populations from Southern (Malawi), East (Uganda) and 33 
West Africa (Benin), we investigated the molecular basis of resistance, revealing strong 34 
differences between the different African regions. The duplicated cytochrome P450 genes 35 
(CYP6P9a and CYP6P9b) which were highly over-expressed in southern Africa are not the 36 
most up-regulated in other regions, where other genes are more over-expressed, including 37 
GSTe2 in West (Benin) and CYP9K1 in East (Uganda). The lack of directional selection on 38 
both CYP6P9a and CYP6P9b in Uganda in contrast to southern Africa further supports the 39 
limited role of these genes outside southern Africa. However, other genes such as the P450 40 
CYP9J11 are commonly over-expressed in all countries across Africa. Here, CYP9J11 is 41 
functionally characterized and shown to confer resistance to pyrethroids and moderate cross-42 
resistance to carbamates (bendiocarb). The consistent over-expression of GSTe2 in Benin is 43 
coupled with a role of allelic variation at this gene as GAL4-UAS transgenic expression in 44 
Drosophila flies showed that the resistant 119F allele is highly efficient in conferring both 45 
DDT and permethrin resistance than the L119. The heterogeneity in the molecular basis of 46 
resistance and cross-resistance to insecticides in An. funestus populations throughout sub-47 
Saharan African should be taken into account in designing resistance management strategies. 48 
49 
Background 50 
Malaria remains one of the main causes of morbidity and mortality in Sub-Saharan 51 
Africa, predominantly in children under 5 years and pregnant mothers (WHO 2015). 52 
Anopheles funestus s.s. is one of the major malaria vectors in Sub-Saharan Africa and is 53 
widely distributed across the continent (GILLIES AND DE MEILLON 1968). The important role 54 
of An. funestus in malaria transmission is supported by recent reports indicating high 55 
Plasmodium falciparum parasite infection rates in this vector in many Sub-Saharan countries 56 
(COETZEE AND KOEKEMOER 2013; DIA et al. 2013). Malaria vector control relies heavily on 57 
the use of a single insecticide class, the pyrethroids. Pyrethroids are safe and fast acting (ZAIM 58 
et al. 2000) and are the only class of insecticides approved for use on insecticide treated 59 
materials such as Long Lasting Insecticide Nets (LLINs)(http://www.who.int/whopes/en/). As 60 
in other malaria vectors, pyrethroid resistance in An. funestus has increasingly been reported 61 
in Sub-Saharan Africa from different regions, including; Southern [South Africa 62 
(HARGREAVES et al. 2000; BROOKE et al. 2001), Mozambique (CASIMIRO et al. 2006; 63 
CUAMBA et al. 2010), Malawi (HUNT et al. 2010; WONDJI et al. 2012)], East [Uganda and 64 
Kenya (MORGAN et al. 2010; MULAMBA et al. 2014) and Tanzania (LWETOIJERA et al. 2014)], 65 
Central [Cameroon  (WONDJI et al. 2011; MENZE et al. 2016)] or West Africa [Benin 66 
((DJOUAKA et al. 2011; DJOUAKA et al. 2016a), Ghana (OKOYE et al. 2008; RIVERON et al. 67 
2016), Senegal (SAMB et al. 2016) and Nigeria (IBRAHIM et al. 2014; DJOUAKA et al. 2016b)]. 68 
These increasing reports of pyrethroid resistance in malaria vectors such as Anopheles 69 
funestus is of great concern as it poses serious threats to the effectiveness of the malaria 70 
vector control tools across the continent (WHO 2012). Thus, the urgent calls to develop and 71 
implement suitable resistance management strategies against malaria vectors, to ensure 72 
sustainable effectiveness of malaria vector control interventions. Understanding the molecular 73 
basis of insecticide resistance in malaria vectors is critical for designing and implementing 74 
these resistance management strategies. 75 
 Cases of pyrethroids resistance reported so far in An. funestus populations are mainly 76 
caused by metabolic resistance mechanisms with no evidence of target-site resistance through 77 
knockdown resistance (kdr) (AMENYA et al. 2008; OKOYE et al. 2008; WONDJI et al. 2012; 78 
RIVERON et al. 2013). Cytochrome P450s are known to be the primary enzyme family 79 
conferring resistance to pyrethroids. Molecular studies conducted in southern Africa notably 80 
in Malawi and Mozambique have revealed that the duplicated P450 genes, CYP6P9a and 81 
CYP6P9b are the main genes driving pyrethroid resistance in this species in this region 82 
(AMENYA et al. 2008; WONDJI et al. 2009; RIVERON et al. 2013). However, studies performed 83 
in Zambia suggested a diminishing role of these two duplicated P450s northwards (RIVERON 84 
et al. 2014a; THOMSEN et al. 2014). Furthermore, a recent study has revealed a similar minor 85 
role of CYP6P9a and CYP6P9b across a south-north transect in Malawi, with low expression 86 
of these two genes in the north in contrast to high level in south, coupled with a nearly fixed 87 
resistant haplotype (BARNES et al. 2016). This variation of expression profiles in Southern 88 
Africa suggests that there could also be significant differences in the underlying genetic 89 
drivers of pyrethroid resistance across African populations of An. funestus. However, the 90 
molecular basis of pyrethroid resistance in An. funestus in other African regions such as in 91 
East or West Africa remains poorly characterised despite the high level of pyrethroid 92 
resistance also reported in these regions (OKOYE et al. 2008; MORGAN et al. 2010; DJOUAKA 93 
et al. 2011; MULAMBA et al. 2014).  94 
Here, using a microarray genome-wide transcription analysis, we characterised the 95 
molecular basis of pyrethroid resistance in this major vector in West and East Africa and 96 
through a comparative analysis with southern African populations, we revealed sharp 97 
difference in the key genes driving resistance in each region. The P450 CYP9J11 commonly 98 
over-expressed in all countries was functionally characterized and shown to confer resistance 99 
to pyrethroids and moderate cross-resistance to carbamates. In addition, allelic variation in the 100 
glutathione S-transferase gene, GSTe2, through the L119F mutation (RIVERON et al. 2014b)  101 
was established to be playing a main role in both DDT and pyrethroid resistance in Benin. 102 
 103 
Methods 104 
Study sites and samples 105 
Blood-fed (F0) females resting indoors were collected between 06.00 a.m. and 12.00 106 
p.m. in Tororo, Eastern Uganda (0.69°N, 34.18°E), in July 2012. Benin samples were 107 
collected in Pahou (6° 23′ N, 2° 13′E) in Southern Benin, West Africa in April 2011. The 108 
Malawian samples were collected in the Chikwawa District (0° 45′ N, 34° 5′E) in Southern 109 
Malawi between July 2009 and April 2010. The F0 collection method and F1 rearing were 110 
conducted as described previously (DJOUAKA et al. 2011; RIVERON et al. 2013; MULAMBA et 111 
al. 2014). All F0 adults used for individual oviposition of the above F1 eggs were 112 
morphologically identified as belonging to the An. funestus group according to the key of 113 
(GILLIES AND COETZEE 1987). A PCR assay was performed using the protocol of 114 
(KOEKEMOER et al. 2002) to confirm that collected F0 adults were An. funestus s.s. The study 115 
samples were 2- to 5-day-old F1 adult permethrin resistant An. funestus s.s. mosquitoes.  116 
 117 
Resistance profile of different populations 118 
The resistance patterns of the three populations to various insecticides was determined 119 
as described previously (DJOUAKA et al. 2011; RIVERON et al. 2013; MULAMBA et al. 2014) 120 
following the WHO protocol (WHO 1998). The Pahou populations of An. funestus from 121 
Benin is highly resistant to DDT (0% mortality after 1h exposure), resistant to both Type I 122 
(permethrin; 66% mortality) and II (deltamethrin; 88% mortality) pyrethroid, resistant to 123 
carbamates (bendiocarb; 64% mortality), but fully susceptible to malathion (Djouaka et al. 124 
2011). The Uganda population from Tororo is resistant to pyrethroids [permethrin (33% 125 
mortality), deltamethrin (20% mortality)] and DDT (61% mortality) but susceptible to other 126 
insecticide classes (MULAMBA et al. 2014). The Malawi population from Chikwawa in 2010 127 
was resistant to pyrethroid [permethrin (47.2 % mortality), deltamethrin (42.3% mortality)] 128 
and carbamates (bendiocarb; 60% mortality), moderately resistant to DDT (87.8% mortality) 129 
and fully susceptible to organophosphates (WONDJI et al. 2012; RIVERON et al. 2013). 130 
 131 
Detection of pyrethroid resistance genes using microarrays 132 
The 8x60k Agilent microarray chip custom designed for An. funestus used for this 133 
study was previously described (RIVERON et al. 2014a). Briefly each chip contains 60mer 134 
probes designed from An. funestus published ESTs from transcriptome sequencing by 454 135 
(8,540) (GREGORY et al. 2011), Illumina (15,527) (CRAWFORD et al. 2010), or An. funestus 136 
cDNAs from GenBank (2850) (2 probes for each EST). It also includes a set of P450 genes 137 
from the rp1 and rp2 QTL genomic regions (WONDJI et al. 2009; IRVING et al. 2012) (3 138 
probes for each gene), the complete set of Anopheles gambiae transcripts (13,000) (1 probe 139 
each) and all of the An. gambiae detoxification genes (DAVID et al. 2005) (3 probes for each 140 
gene). In Benin, we also used the other 4x44k An. funestus chip (A-MEXP-2245), previously 141 
described (RIVERON et al. 2013) in a triangular experimental design comparing resistant (R), 142 
control (C) and susceptible (S) samples. 143 
The Picopure RNA Isolation Kit (Arcturus) was used to extract total RNA from three 144 
biological replicates, each made of batches of ten 2- to 5-day-old F1 An. funestus from each 145 
field sample which had survived exposure to 0.75% permethrin for 1h (R). The same was 146 
done also for the fully susceptible laboratory strain FANG (S). Mosquitoes from Benin not 147 
exposed to insecticide (C) were also extracted. The RNA extraction was performed as 148 
previously described (RIVERON et al. 2014a). Complementary RNA (cRNA) was amplified 149 
from each sample using the Agilent Quick Amp Labeling Kit (two-color) following the 150 
manufacturer’s protocol. The cRNA samples from the susceptible strain FANG (S) were 151 
labeled with the cy3 dye and cRNAs from the resistant samples (R) were labeled with cy5 152 
dye. The cRNA quantity and quality were assessed before labeling using the NanoDrop and 153 
Bioanalyzer. Labeled cRNAs were hybridized to the arrays for 17 h at 65°C according to the 154 
manufacturer’s protocol. Five hybridizations were performed for each sample by swapping 155 
the biological replicates. The Agilent GeneSpring GX 13.0 software was used to analyze the 156 
microarray data. The differentially expressed genes were identified using a threshold of 2-157 
fold-change (FC) and a statistical significance of P<0.01 with Benjamini-Hochberg correction 158 
for multiple testing. The BLAST2GO program was used to predict the functions of all the 159 
transcripts used to design the microarray chip (CONESA et al. 2005; GOTZ et al. 2008). Gene 160 
Ontology (GO) enrichment analyses were preformed using BLAST2GO to detect the major 161 
GO terms over-represented among the sets of probes up-regulated in various hybridisations 162 
and countries in comparison to the reference set made of the entire transcript set on the 163 
microarray chip. The Fisher's test was used to assess the statistical significance of these tests. 164 
 165 
 166 
Quantitative RT-PCR validation of the candidate resistance genes  167 
Quantitative reverse transcription PCR (qRT-PCR) assays were performed to validate 168 
microarray results for the key candidate genes. 1µg of RNA from each of the three biological 169 
replicates; the Resistant (R), Control (C) and FANG (S) was used as a template for 170 
complementary (cDNA) synthesis using the superscript III (Invitrogen) following 171 
manufacturer’s guide. The qRT-PCR was carried out as previously described (KWIATKOWSKA 172 
et al. 2013; RIVERON et al. 2013) with the relative expression level and FC of each target gene 173 
in R and C relative to S calculated according to the 2-ΔΔCT method (SCHMITTGEN AND LIVAK 174 
2008) after normalization with the housekeeping genes ribosomal protein S7 (RSP7; 175 
AFUN007153) and actin5C (AFUN006819). The primers are listed in Table S1. 176 
 177 
Heterologous expression of candidate genes in E. coli 178 
Cloning of CYP9J1 for expression in E. coli: The full-length CYP9J11 was amplified 179 
from cDNAs (used for qRT-PCR) and cloned into the pJET1.2/blunt cloning vector (Thermo 180 
Scientific). The primers used are listed in Table S1 as CYP9J11Full F and R. After sequence 181 
analysis, one clone predominant in the three countries was selected for functional 182 
characterization. This CYP9J11 allele was fused to a bacterial ompA+2 leader sequence and 183 
expressed in E. coli JM109 cells using the pCW-ori+ vector as previously described 184 
(PRITCHARD et al. 1998; MCLAUGHLIN et al. 2008; STEVENSON et al. 2011). Briefly, a DNA 185 
fragment containing the coding sequence for the ompA+2 signal peptide with a downstream 186 
alanine-proline linker and approximately the first 20 nucleotides of CYP9J11 was first 187 
amplified using 50ng of E. coli JM109 DNA as the template (Primer sets in Table S1). Next, 188 
this CYP9J11 clone and the ompA+2 PCR fragment were used as templates in a fusion PCR 189 
under the same conditions described previously (RIVERON et al. 2014a). The full-length 190 
sequence of CYP9J11 incorporating the ompA+2 leader was ligated into a modified pCW-191 
ori+ vector plasmid, pB13 (PRITCHARD et al. 1998), via EcoRI and XBaI sites to produce 192 
pB13::ompA+2-CYP9J11.  This construct was also sequenced to confirm the absence of PCR 193 
errors.  194 
Membrane preparation: Membranes containing CYP9J11 were obtained by co-195 
transforming the E. coli cells JM109 with pB13::ompA+2-CYP9J11 with a plasmid 196 
containing the An. gambiae cytochrome P450 reductase, pACYC-AgCPR (MCLAUGHLIN et 197 
al. 2008). The expression of CYP9J11, membrane isolation and determination of P450 198 
content were carried out as previously described (MCLAUGHLIN et al. 2008; STEVENSON et al. 199 
2011). The membranes were stored in aliquots at -80ºC and assayed for total protein 200 
concentration using NanoDrop spectrophotometer, P450 concentration (OMURA AND SATO 201 
1964) and CPR activity by monitoring cytochrome c reduction (STROBEL AND DIGNAM 1978). 202 
The histidine-tagged An. gambiae cytochrome b5 was generated as previously described by 203 
Stevenson et al. (2011) and used for the metabolism assays. 204 
Metabolism assays: In vitro metabolism reactions between pyrethroids (deltamethrin 205 
and permethrin) and carbamates (bendiorcab and propuxur) and membranes expressing 206 
CYP9J11 were performed as previously described (STEVENSON et al. 2011; IBRAHIM et al. 207 
2016a) in the presence of CPR with cytochrome b5. The reactions consisted of the following: 208 
45pmole of P450, 0.2M Tris HCl pH 7.4, 0.25mM MgCl2, 1mM glucose-6-phosphate, 0.1mM 209 
NADP+ (Melford), 1 unit/ml glucose-6-phosphate dehydrogenase (G6PDH), 0.8µM 210 
cytochrome b5 and 0.2mM of test insecticide in a final volume of 200ml.  211 
HPLC analysis: Detection of the reaction outcome followed standard protocol 212 
(STEVENSON et al. 2012) with the reactions stopped by addition of 0.1 ml ice-cold methanol 213 
and incubation for 5 mins with shaking to dissolve all available pyrethroids. After a 214 
centrifugation of the samples, 150µl of the supernatant was transferred into HPLC vials. 100 215 
µl sample was loaded into an isocratic mobile phase of 90% methanol and 10% water with a 216 
flow-rate of 1 ml/min, and substrate peaks were separated on a 250 mm C18 column (Acclaim 217 
TM
 120, Dionex) at 23ºC. The quantity of pyrethroid remaining in the samples was determined 218 
by reverse-phase HPLC with a monitoring absorbance wavelength of 226nm (Agilent 1260 219 
Infinity). Percentage depletion was calculated by comparing the area of the chromatogram 220 
from incubation with NADPH regeneration system to the tubes in which NADP+ was not 221 
added (NADP-). HPLC conditions for analysis of the non-pyrethroid insecticides was as 222 
described in a previous study (IBRAHIM et al. 2016c).   223 
Turnover and kinetic assays: To determine the turnover of CYP9J11 with pyrethroids 224 
and bendiocarb, experiments with deltamethrin, permethrin and bendiocarb were performed in 225 
with incubation time varied from 0 to 30 minutes. For kinetic constants, incubation was 226 
carried out with 20µM each of deltamethrin, permethrin and bendiocarb for 30 minutes. The 227 
turnover and steady-state kinetic parameters (KM and Vmax) were calculated as previously 228 
described (IBRAHIM et al. 2015b) using the enzyme kinetic module of GraphPad Prism 6.03 229 
(GraphPad Software Inc., La Jolla, CA, USA). Catalytic constants and efficiencies were 230 
determined from the steady-state parameters. 231 
 232 
Transgenic expression of candidate genes in Drosophila strains and tests with 233 
insecticides 234 
To functionally validate the role of An. funestus CYP9J11 (an ortholog of CYP9J5 in 235 
An. gambiae) in conferring pyrethroid resistance (CYP9J11 is consistently over-expressed in 236 
all 3 countries), transgenic Drosophila melanogaster flies expressing this gene were 237 
generated using the GAL4/UAS system. This is to establish whether CYP9J11 over-238 
expression alone could confer resistance to pyrethroids. The construction of the transgenic 239 
strain followed the protocol we successfully used for the P450s CYP6P9a and CYP6P9b 240 
(RIVERON et al. 2013) and CYP6M7 (RIVERON et al. 2014a).  241 
Briefly, the same predominant clone used for transgenic expression was selected to 242 
construct transgenic flies which was cloned into the pUASattB vector using primers 243 
containing restriction sites for BagII and XbaI (see Table S1). The PhiC31 system was used to 244 
generate the transgenic line UAS-CYP9J11 by Genetic Services (MA, USA). Ubiquitous 245 
expression of the transgene CYP9J11 in adult F1 progeny (experimental group) was obtained 246 
after crossing virgin females from the driver strain Act5C-GAL4 ["y[1] w[*]; P(Act5C-247 
GAL4-w)E1/CyO","1;2"] (Bloomington Stock Center, IN, USA) with homozygote UAS-248 
CYP9J11 males. Similarly, adult F1 control progeny (control group) with the same genetic 249 
background as the experimental group but without expression of CYP9J11 were obtained by 250 
crossing virgin females from the driver strain Act5C-GAL4 and UAS recipient line males 251 
(which do not carry the pUASattb-CYP9J11 insertion). 252 
Insecticide contact bioassays for both experimental and control F1 Drosophila 253 
melanogaster females were performed as previously described (RIVERON et al. 2014a) using 254 
post-eclosion females that were 2 to 5 days old for contact assay with the pyrethroids 255 
deltamethrin (0.15%) and permethrin (2%)-impregnated filter papers prepared in acetone and 256 
Dow Corning 556 Silicone Fluid (BHD/Merck, Germany). 20-25 flies were placed in 257 
individual vial containing respective insecticide papers, and the mortality plus knockdown 258 
was scored after 1 h, 2 h, 3 h, 6 h, 12 h and 24 h, 36 h and 48 h of exposure to the insecticide. 259 
For all assays, at least 6 replicates were performed. Student’s t-test was used to compare the 260 
mortality plus knockdown of the experimental group against the control group. 261 
Investigating the role of allelic variation at GSTe2 in the permethrin resistance: 262 
Due to the over-expression of GSTe2 in mosquitoes resistant to permethrin in Benin, we used 263 
the transgenic expression in Drosophila to assess whether the allelic variation observed at this 264 
gene with the L119F mutation was playing a role in the observed resistance. A transgenic line 265 
was generated using the susceptible L119-GSTe2 allele following the same protocol 266 
described previously for the resistant allele 119F-GSTe2 as well as for the bioassays with 267 
permethrin, deltamethrin but also DDT (RIVERON et al. 2014b). Student’s t-test was used to 268 
compare the mortality plus knockdown of the L119-GSTe2 group against the control group 269 
and 119F-GSTe2 group.  270 
 271 
Genetic diversity of candidate resistance genes between different An. funestus 272 
populations from different regions of Africa 273 
Genetic variability of CYP9J11: The full-length coding region of CYP9J11 was 274 
amplified from cDNA of permethrin-resistant samples from Malawi, Uganda and Zambia to 275 
assess the polymorphism of this gene. The Zambia mosquitoes were collected in Katete 276 
district (14°11'0"S, 31°52'0"E) in 2010 as previously described (RIVERON et al. 2014a). The 277 
amplification was performed using the same cDNA synthesized for qRT-PCR with the 278 
Phusion polymerase (Thermo Scientific, USA), which was cloned and sequenced as described 279 
above.  280 
Comparative genetic diversity of CYP6P9a and CYP6P9b between East and 281 
southern Africa: To assess whether previously detected directional selection associated with 282 
high over-expression of CYP6P9a and CYP6P9b genes in Southern Africa was also present in 283 
East Africa, mosquitoes from Tororo in Uganda were compared to those from Chikwawa in 284 
Malawi (RIVERON et al. 2013). Genomic fragment of both genes spanning the full-length 285 
coding region and a portion of the 5’UTR region were amplified and directly sequenced in 10 286 
susceptible (dead after 1h exposure) from Tororo and 10 resistant mosquitoes (alive after 1h 287 
exposure) to 0.75% permethrin. The primers used are listed in Table S1. Polymorphic 288 
positions were detected through manual analysis of sequence traces using BioEdit and as 289 
sequence differences in multiple alignments using ClustalW (THOMPSON et al. 1994). DnaSP 290 
5.1 (ROZAS et al. 2003) was used to define the haplotype phase (through the Phase program) 291 
and to assess genetic parameters of each gene such as nucleotide diversity (π) and haplotype 292 
diversity. A maximum likelihood phylogenetic tree of the haplotypes for each gene was 293 
constructed using MEGA 5.2 (TAMURA et al. 2007) to assess the potential correlation 294 
between haplotypes and resistance phenotypes.  295 
 296 
Data availability 297 
The microarray data from this study were submitted to Array Express, accession 298 
numbers E-MTAB-5375; E-MTAB-5376 and E-MTAB-5424. The DNA sequences reported 299 
in this paper have been deposited in the GenBank database (accession numbers: KJ150626-300 
KJ150674). 301 
 302 
Results  303 
Transcription profiling of the pyrethroid resistant population of Uganda 304 
To detect the set of genes associated with permethrin resistance in Uganda, the 8x60k 305 
microarray chip was used to compare mosquitoes alive to permethrin exposure to control 306 
(non- exposed) (R-C) and to the fully susceptible lab strain FANG (R-S). The control 307 
mosquitoes were also compared to the susceptible FANG strain (C-S). High numbers of 308 
probes were significantly differentially expressed (P<0.05) for the R-S (7,346) and C-S 309 
(7,479) comparisons (Figure 1A) most likely due to extensive genetic differences between the 310 
samples. In contrast, for the R-C comparison a lower number of probes differentially 311 
expressed (827) were observed as previously described in other similar studies (RIVERON et 312 
al. 2013) due to the high level of resistance in the population. Consequently, only 55 probes 313 
were commonly differentially expressed in all three comparisons. 314 
 R-S/C-S/R-C: The cytochrome P450 CYP4C27 [Afun012777 using the ID system set 315 
by CRAWFORD et al. (2010)] was the only detoxification gene commonly over-expressed in R-316 
C, R-S and C-S with highest fold change in R-S (FC10.3) (Table 1). Other genes had no 317 
annotation or no previous association with insecticide resistance such as an acyl-oxidase 318 
Afun004337 (AGAP011798-RA). 319 
R-S/C-S only: Among the most over-expressed genes commonly observed in R-S and 320 
C-S were proteases such as a trypsin-related protease (Afun008293) which was the top up-321 
regulated with FC187.8 in R-S and 83.07 in C-S. Other highly over-expressed proteases 322 
included chymotrypsin 1 (Afun013921) with FC64.4 in R-S and 49.5 in C-S. High over-323 
expression of proteases is commonly reported in resistant mosquitoes either Anopheles 324 
(KWIATKOWSKA et al. 2013; RIVERON et al. 2013), or Aedes albopictus (ISHAK et al. 2016). 325 
Several detoxification genes were commonly up-regulated in both comparisons with a 326 
predominance of cytochrome P450s notably CYP6M7 (Afun007663), which was the most 327 
over-expressed with FC70.1 in R-S and 24 in C-S. This P450 has previously been shown to 328 
metabolize pyrethroids (RIVERON et al. 2014a). Other highly over-expressed P450 genes 329 
included CYP9K1 (Afun007769) with a higher fold change (FC21.5) in R-S than previously 330 
observed in southern Africa suggesting a higher role played by this gene in Uganda. The 331 
CYP307A1 (Afun015331) exhibited a high FC in R-S (FC16.6). Other cytochrome P450s 332 
included CYP6 subfamily genes such as CYP6Z1, CYP6P5, CYP6P4, CYP6Z3 and noticeably 333 
the CYP6M8 (Afun006930), of which the ortholog from An. gambiae, CYP6M2 is responsible 334 
for pyrethroid resistance in this species (STEVENSON et al. 2011; MITCHELL et al. 2012) but 335 
not previously associated with such resistance in An. funestus. A particular transcript 336 
(Afun07369) had a close hit to CYP6P9a but none of the common probes for this gene highly 337 
over-expressed in southern Africa was observed in Uganda. CYP4 subfamily genes over-338 
expressed included CYP4H17, CYP4C36 and CYP4K2 whereas, CYP9J11, from the CYP9 339 
subfamily, was also over-expressed in both comparisons. Glutathione S-transferases were also 340 
significantly overexpressed in pyrethroid resistant mosquitoes from Uganda compared to the 341 
susceptible FANG strain notably genes of the epsilon class, including GSTe1 (Afun013481) 342 
(FC6.6 and 5.6 respectively in R-S and C-S), GSTe5 (Afun009866) and GSTe2 (Afun000045) 343 
which with FC of 2.9 and 2.1 exhibits a lower FC than the level observed in West Africa 344 
(RIVERON et al. 2014b). Glutathione-S transferase genes (GSTs) from the Delta class were 345 
also over-expressed, including GSTD3 (Afun008354) (FC6.6 and 5.1) and GSTD1-5 346 
(Afun007499). Other over-expressed detoxification gene families included sulfotransferases 347 
(with Afun013870 having a high FC of 11.9 and 14.8), carboxylesterases, aldehyde oxidases, 348 
ABC transporters and other genes commonly associated with metabolic resistance to 349 
pyrethroid (Table 1). Cuticular protein genes were also among the over-expressed genes. 350 
Transcription profiling of the pyrethroid resistant population of Benin 351 
A similar approach was used in Benin using the 4x44k chip, as done before the design 352 
of the 8x60k. High numbers of probes were significantly differentially expressed for the R-S 353 
(5,617) and C-S (7,735) comparisons (Figure 1B) most likely due to extensive genetic 354 
differences between the samples. Contrary to Uganda, the R-C comparison also showed a 355 
high number of probes differentially expressed (6,033) leading to a higher number of probes 356 
commonly differentially expressed in all three comparisons (1,890). 357 
R-S/C-S/R-C: The glutathione S-transferase GSTe2 (Combined_c920) was the only 358 
detoxification gene commonly over-expressed in R-C, R-S and C-S (Table 2). Three probes 359 
from this gene consistently had a higher over-expression in the R-S comparison from 360 
permethrin surviving mosquitoes vs susceptible FANG than in the C-S comparison supporting 361 
its association with permethrin resistance in addition to its role as a main DDT metabolizer as 362 
previously established (RIVERON et al. 2014b). 363 
Common probes between two comparisons: Among probes significantly over-364 
expressed in at least two comparisons, the cytochrome P450 genes CYP6P9a and CYP6P9b 365 
were up-regulated in both C-S and R-S but with relatively low levels compared to previously 366 
reported levels in southern Africa (<6.4 FC). Two probes of the CYP9J11 were also up-367 
regulated but between R-C and R-S only (Table 2). Other detoxification genes were up-368 
regulated but only in one comparison. Those found in R-S only included the cytochrome 369 
P450s CYP6Z1 (three probes), CYP6Z3, CYP6P1 and another probe for CYP6P9a. It also 370 
included two ABC transporter genes (probes from An. gambiae transcripts AGAP002182 and 371 
AGAP001777 respectively), an aldehyde dehydrogenase and cuticular protein genes (Table 372 
2). Genes only present in the C-S comparison included an alpha-esterase (COEAE1G; FC5.1) 373 
and an UDP glycosyl transferase. Other detoxification genes were up-regulated only in the R-374 
C comparison including the cytochrome P450s CYP6AA1, CYP6P5 and two GSTs (Table 2). 375 
GO enrichment analysis 376 
Blast2go enrichment analysis for the set of probes up-regulated in R-S and C-S 377 
comparisons did not detect many GO terms related to detoxification process in mosquitoes. In 378 
the case of the C-S comparison in Benin for example, the major GO terms over-represented 379 
mainly belong to serine-type endopeptidase activity, odorant binding activity, protein DNA 380 
complex and others (Figure S1). Similar results were obtained for other comparisons. The 381 
lack of GO terms associated with detoxification is similar to previous studies with this 382 
microarray chip in An. funestus (RIVERON et al. 2013; RIVERON et al. 2014a). This is probably 383 
caused by the poor annotation of the set of Expressed Sequences Tags (ESTs) used for the 384 
microarray chip and the composite nature of the microarray chip made of transcripts from 385 
different sources. 386 
Regional comparison of expression profiles between West (Benin), East (Uganda) 387 
and southern (Malawi) Africa 388 
The variation in the underlying resistance mechanisms to pyrethroid between 389 
geographical regions in Africa was analyzed by comparing the expression profiles from Benin 390 
and Uganda to that from Malawi in southern Africa using the 8x60k chip. The number of 391 
significantly differentially expressed probes is presented in Figure 1C. 392 
Genes common in all regions: Among the genes the most up-regulated in all three 393 
regions, were a trypsin-related protease gene (Afun008293), the P450 CYP6M7, the 394 
argininosuccinate lyase and a glycogenin gene. However, although over-expressed in all 395 
regions, the expression levels vary significantly for some genes such as for CYP6M7 which 396 
has a FC of 131.9 in Benin but only 12.5 in Malawi (Table 3). Among the detoxification 397 
genes commonly over-expressed in all three regions, cytochrome P450s were again dominant. 398 
Most of these P450 genes showed a similar level of expression in all the 3 countries and 399 
included CYP4H17, CYP6Z1, CYP6M4, CYP6M2, CYP9J11, CYP9J13, CYP304B1 and a 400 
gene close to CYP6P9a (Afun007369). Another P450 CYP9K1 although commonly over-401 
expressed in all 3 countries was significantly highly present in Uganda (FC16.1) than in 402 
Malawi (FC2.4) and Benin (FC6.2) suggesting a bigger role of this gene in Uganda. Other 403 
commonly expressed detoxification genes included am aldehyde oxidase (AGAP006220) and 404 
a UDP glucuronosyl transferase (AGAP006222).  405 
Genes common in only two regions: Analysis of the list of genes commonly over-406 
expressed only in two regions revealed that for Uganda and Benin, the glutathione S-407 
transferases GSTe1, and GSTd3 were common to both countries just as the P450s CYP307A, 408 
CYP314A1 and CYP315A. For those over-expressed only in Uganda and Malawi, the P450 409 
CYP4C27 was detected although with a higher expression in Uganda (FC10.3) than in 410 
Malawi (FC2.1). The CYP4C36 was also up-regulated in both countries similar to GSTd1-5. 411 
Other genes are also listed in Table S2. The list of genes only over-expressed in Malawi and 412 
Benin is dominated by the CYP6P9a and CYP6P9b with several probes but with a far higher 413 
over-expression in Malawi for both gene (e.g. FC39.4 for CYP6P9a in Malawi vs only FC4.3 414 
in Benin) suggesting that both genes are mainly driving resistance in southern Africa. 415 
Some genes common to all countries were detected through different probes such as 416 
for GSTe2 which in Benin and Malawi was detected by the probes against Combined_c920 417 
transcript whereas in Uganda and Malawi it was through the probes for Afun000045 418 
transcript showing the impact of sequence polymorphism in the microarray results. 419 
Quantitative RT-PCR: Key genes exhibiting striking differences between regions 420 
(CYP6P9a, CYP6P9b and GSTe2) or commonly over-expressed in all three countries 421 
(CYP9J11) were further validated by qRT-PCR. Analysis of the expression patterns 422 
confirmed the differences observed with microarray as both CYP6P9a and CYP6P9b were 423 
highly over-expressed only in Malawi but just barely in Uganda and Benin as seen with 424 
microarray (Figure 1D). Similarly, the GSTe2 was highly over-expressed in Benin permethrin 425 
resistant individuals (FC 73.1), but only very low-level expression of this gene was observed 426 
in Uganda and Malawi. The common over-expression of the CYP9J11 was also validated in 427 
all three countries although at lower fold change compared to the other genes. 428 
Functional characterization of key genes commonly over-expressed in all 429 
countries 430 
Several genes (notably P450s) commonly over-expressed in the three geographical 431 
regions are located in the chromosomal regions spanning the three QTLs (rp1, rp2 and rp3) 432 
previously detected for pyrethroid resistance in An. funestus (WONDJI et al. 2009). If the key 433 
genes driving resistance in rp1 and rp2 have already been characterized (IRVING et al. 2012; 434 
RIVERON et al. 2013), the genes driving resistance in rp3 remain uncharacterized. The 435 
CYP9J11 over-expressed in all three regions and located in the 3L chromosomal region 436 
spanning the rp3 QTL could be the pyrethroid metabolizer gene in this QTL. To validate this 437 
hypothesis, we performed a functional characterization of this gene.  438 
Polymorphism analysis of CYP9J11: Analysis of the genetic variability of CYP9J11 439 
full-length cDNA (1644 bp) for five clones each from Malawi and Zambia and four from 440 
Uganda revealed a high polymorphism of this gene, with an average of 93 polymorphic sites 441 
observed for all combined 14 sequences and 17 amino acid changes observed in total (Table 442 
S3). No evidence of directional selection was detected on CYP9J11 as shown by the lack of 443 
significant Tajima D and Fu and Li D’ estimates. No specific clades per the location of origin 444 
was observed between haplotypes although the genetic distance tree revealed a closer genetic 445 
similarity between Malawi and Zambia than Uganda as expected from geographical distance 446 
(Figure 2A and 2B).   447 
Functional validation of CYP9J11 using heterologous expression in E. coli and 448 
metabolism assays 449 
Pattern of expression of CYP9J11: On average CYP9J11 protein consistently 450 
expressed at low concentration (0.13±0.007nmol/mg protein) compared with previous 451 
estimates reported for CYP6M7 (0.15±0.0nmol/mg protein) and for CYP6P9a (0.42-1.0 452 
nmol/mg) and CYP6P9b (0.35-0.42nmol/mg), respectively.  453 
Assessment of CYP9J11 pyrethroid activities and cross-resistance using 454 
metabolism Assays: Disappearance of 20 µM insecticides substrates was determined after 90 455 
minutes of incubation with the recombinant CYP9J11 in the presence of cytochrome b5 and 456 
NADPH regeneration system. CYP9J11 metabolized permethrin and deltamethrin with 457 
significant depletions of 88.05%±3.23 (p<0.0001) and 95.05%+0.74 (p<0.0001) respectively 458 
(Figure 3A). These depletions were higher than obtained with both CYP6P9a and CYP6P9b 459 
alleles (RIVERON et al. 2013; RIVERON et al. 2014a). Carbamates bendiocarb and propoxur as 460 
well as the organophosphate malathion were screened to investigate potential cross resistance 461 
by CYP9J11. Low and non-significant depletion was observed against DDT and malathion 462 
(Figure 3A), as observed previously from CYP6P9a, CYP6P9b and CYP6M7. This result is 463 
consistent with malathion susceptibility across Africa so far. CYP9J11 significantly depleted 464 
bendiocarb; but with a with lower depletion of 38.34%±7.01 (p<0.05) than previously 465 
reported for CYP6Z1 ((54.72%±0.45, p<0.05) (IBRAHIM et al. 2016a). In contrast to 466 
incubations with CYP6M7, CYP6P9a and CYP6P9b (less than 10% depletions), CYPJ11-467 
mediated metabolism of bendiocarb proceeded with polar metabolites eluting in the beginning 468 
of the HPLC chromatogram (Figure 3B).  Initial reaction of carbamate metabolism has been 469 
described to produce very polar products that remain at the origin of the chromatogram 470 
(KUHR 1970) and such highly polar metabolites have been recently described in metabolisms 471 
assay with bendiocarb and An. funestus CYP6Z1 protein (IBRAHIM et al. 2016b). 472 
Kinetics parameters of CYP9J11 metabolism of insecticides: The CYP9J11-mediated 473 
metabolism of permethrin and deltamethrin follows Michaelis-Menten pattern (Figure 3A and 474 
3B), but a decline in activity was observed with deltamethrin above 12.5µM concentration, 475 
attributed to substrate or product inhibition. The turnover (Kcat) and KM obtained with 476 
permethrin was 9.260min-1 ± 1.048 and 14.39µM ± 3.12 leading to a catalytic efficiency of 477 
0.643min-1µM-1± 0.157. The turnover for deltamethrin (4.338min-1 ± 1.381) was on average 478 
half the value obtained with permethrin, but the affinity of CYP9J11 towards deltamethrin 479 
was surprising higher (KM of 7.957± 1.31).  The catalytic efficiency of CYP9J11 for 480 
deltamethrin was calculated as 0.545min-1µM-1± 0.195, lower than obtained with permethrin. 481 
The catalytic efficiency of this enzyme towards permethrin is higher than obtained  from An. 482 
funestus pyrethroid metabolizers  CYP6P9a and CYP6P9b (RIVERON et al. 2014a).  483 
CYP9J11 was also tested with 20µM bendiocarb and was shown to behave in 484 
allosteric fashion with this carbamate insecticide, with positive cooperativity (Hill coefficient, 485 
h = 2.29±0.38) as described to be the case of some P450s (ATKINS 2004). CYP9J11 portrayed 486 
sigmoidal curve with relatively low Khalf (lower than KM obtained with pyrethroids) and low 487 
maximal catalytic rate (Figure 3C). Dose-response curve was thus modelled using the 488 
GraphPad prism with relevant module as described (COPELAND 2004). The Vmax and Khalf 489 
(KM) for bendiocarb were calculated as 0.04min-1 ± 0.005 and 0.75µM ± 0.2 leading to a very 490 
low catalytic efficiency of 0.053min-1µM-1± 0.0157, 12 time lower than compared with the 491 
values obtained with permethrin.  492 
Transgenic expression of candidate genes in Drosophila flies 493 
Validation of role of CYP9J11: To confirm that CYP9J11 over-transcription can 494 
alone confer pyrethroid resistance, transgenic D. melanogaster individuals were generated 495 
expressing CYP9J11 (derived from permethrin resistant field mosquitoes from Uganda) under 496 
the control of the ubiquitous Act5C-GAL4 driver. Contact bioassays performed with 2% 497 
permethrin (type I pyrethroid) and 0.15% deltamethrin (type II) revealed that CYP9J11 over-498 
transcription alone is sufficient to confer resistance to this class of insecticide. For 499 
deltamethrin, the flies over-expressing CYP9J11 were resistant with a significantly reduced 500 
mortality/knockdown rate compared to that observed for control flies (Figure 4A). 501 
Significantly reduced mortality/knockdown rates were recorded at all the nine different 502 
exposure times for transgenic Act5C-CYP9J11 individuals when compared with the control 503 
group not expressing CYP9J11. For example, mortality rates were 1.04±1 vs. 50.3±4.4% 504 
(P<0.001) at 1h, 9.5±1.7 vs. 74.7±6.32% (P<0.001) at 2h and 56.03±4.6 vs. 98.3±3.3% 505 
(P<0.001) at 24h (Figure 4A).  These results demonstrate that CYP9J11 over-transcription 506 
alone is sufficient to confer resistance to deltamethrin. For permethrin, significantly reduced 507 
mortality/knockdown rate was recorded for transgenic Act5C-CYP9J11 flies when compared 508 
with the control after 1h exposure (3.33±3.3 vs. 18.36±3.8%; P<0.05). However, similar 509 
mortality rates were recorded for both experimental and control samples at the rest of the 510 
exposure times, with no significant differences observed (Figure 4B).  511 
Confirmation of role of allelic variation of GSTe2 in both DDT and pyrethroid 512 
resistance: Due to the consistent over-expression of GSTe2 in permethrin resistant 513 
mosquitoes in Benin where the L119F mutation is fixed, the role of the allelic variation on 514 
this gene was investigated using the transgenic expression. Comparative bioassays performed 515 
between a transgenic line expressing the susceptible L119 allele and another one expressing 516 
the 119F resistant allele revealed that the 119F mutation confers a higher resistance against 517 
both DDT and permethrin. For DDT, no mortality is observed in the flies expressing the 518 
resistant 119F allele for all the different exposure times, whereas significantly higher 519 
mortality rates were observed for the flies expressing the susceptible L119 allele from 24h to 520 
72h exposure time (2.2% to 63%; P<0.001) (Figure 4C). However, the fact that these 521 
mortality rates for flies expressing the susceptible L119 allele were lower than for flies not 522 
expressing the GSTe2 (2.22±1.4, 18.65±7.1 and 62.69±9.6% vs. 85.12±8.4, 98.33±1.7 and 523 
100%; P<0.001; respectively at 24, 48 and 72h) suggests that even the over-expression on the 524 
susceptible allele provide resistance against DDT in flies, but at a significantly lower level 525 
than with the 119F resistance allele. Bioassays with permethrin revealed that only the flies 526 
expressing the resistant 119F allele had significantly lower mortality rate compared to the 527 
control flies not expressing GSTe2 (2.78±2.7, 10.52±2.1, 16.74±4.3 and 46.40%±6.07 vs. 528 
27.98±8.3, 55.44±10.4, 69.60±8.4 and 74.81±7.8%; P<0.01; respectively at 1, 2, 3 and 6h 529 
exposure time) (Figure 4D). Flies expressing the susceptible L119 allele showed the same 530 
high mortality rates as the control flies.  531 
CYP6P9a and CYP6P9b polymorphisms in Uganda in comparison to southern 532 
Africa 533 
A comparative analysis of the polymorphism pattern of the duplicated P450 genes 534 
CYP6P9a and CYP6P9b was performed between permethrin resistant and susceptible 535 
mosquitoes from Uganda and those from Malawi. The aim was to assess whether the low 536 
expression of these genes in Uganda correlated with a higher genetic diversity of both genes 537 
in contrast to southern African where a high over-expression was associated with a directional 538 
selection with reduced genetic diversity (RIVERON et al. 2013; RIVERON et al. 2014a). 539 
Overall, both CYP6P9a and CYP6P9b genes exhibit a higher genetic diversity in Uganda than 540 
in Malawi as shown by the number of substitutions (50 vs. 13 for CYP6P9a; 45 vs. 12 for 541 
CYP6P9b), haplotypes (15 vs. 5 for CYP6P9a; 4 vs. 2 for CYP6P9b), and estimates of genetic 542 
diversity or number of non-synonymous substitutions (Table S3). This higher genetic 543 
diversity of both genes in Uganda correlates with their low over-expression and support a 544 
lower role of both genes in Uganda. However, the maximum likelihood trees of haplotypes of 545 
both genes for Uganda and Malawi (Figure 5A and 5B) revealed that for CYP6P9a, four 546 
haplotypes from resistant mosquitoes clustered with haplotypes from Malawi. These Uganda 547 
haplotypes also exhibit the insertion of two AAs [CAAAAAA(AA)] in the promoter region 548 
characteristic of southern African resistant haplotypes (IBRAHIM et al. 2015a). For both genes, 549 
haplotypes of both countries cluster in separate clades (Figure 5A and 5B). 550 
Discussion 551 
Elucidation of resistance mechanisms to insecticide in mosquito vectors of tropical 552 
diseases such as malaria is a prerequisite for a better management of the growing problem of 553 
resistance to existing insecticide classes in public health sectors. If progress has been made in 554 
assessing the local transcription profiles associated with pyrethroid resistance in malaria 555 
vectors in Africa, generating a broader view of the molecular basis of resistance continent-556 
wide has been limited. The regional comparison of the transcription profile of pyrethroid 557 
resistance in An. funestus across Africa revealed three main lessons discussed below.  558 
1-The transcription profile of pyrethroid resistance is not uniform across the 559 
continent  560 
The genome-wide analysis of the transcription profile associated with pyrethroid 561 
resistance highlighted a common trait, the predominant role of cytochrome P450 genes in the 562 
metabolic resistance observed in An. funestus population as previously reported in southern 563 
Africa (RIVERON et al. 2013; RIVERON et al. 2014a) and in other mosquito species such as An. 564 
gambiae (MITCHELL et al. 2012; KWIATKOWSKA et al. 2013) or in Aedes (STRODE et al. 2008; 565 
BARIAMI et al. 2012; SAAVEDRA-RODRIGUEZ et al. 2012; ISHAK et al. 2016). However, the 566 
drastic difference in the expression levels of key P450s suggests that the origin of resistance is 567 
not the same across the continent and that there were independent selection events of 568 
resistance to pyrethroids in various populations. A clear example is that provided by the 569 
expression profile of the duplicated P450s CYP6P9a and CYP6P9b, the main pyrethroid 570 
resistance genes in southern African populations of An. funestus (AMENYA et al. 2008; 571 
RIVERON et al. 2013; RIVERON et al. 2014a), but which from this study, seem to play no or 572 
little role in East Africa as further supported by their high genetic diversity in Uganda than in 573 
Malawi but also in West (Benin and Ghana) and Central Africa (Cameroon) (BARNES et al. In 574 
Press). Such drastic variation is also in line with the gradual reduced expression of CYP6P9a 575 
and CYP6P9b in Zambia compared to Malawi and Mozambique (RIVERON et al. 2014a; 576 
THOMSEN et al. 2014; BARNES et al. 2016) and suggest barriers to gene flow previously 577 
detected between African populations of this mosquito species (MICHEL et al. 2005; BARNES 578 
et al. In Press).  Variation in the transcription profiles of insecticide resistance genes are also 579 
reported in other mosquito species such as An. gambiae where P450 genes such as CYP6P3 580 
and CYP6M2 highly over-expressed in West (MITCHELL et al. 2012; KWIATKOWSKA et al. 581 
2013) and in Central (FOSSOG TENE et al. 2013; ANTONIO-NKONDJIO et al. 2016) Africa are 582 
not significantly expressed in the southern populations in Zambia (THOMSEN et al. 2014). 583 
Equally also, in contrast the P450 CYP6P4 from An. arabiensis has been shown to be a major 584 
driver of  pyrethroid resistance in populations from Chad (IBRAHIM et al. 2016c) and Sudan 585 
(ABDALLA et al. 2014). It is therefore important to avoid generalising the underlying 586 
molecular basis of resistance across countries or the continent but rather to determine as much 587 
as possible the main resistance genes in the different countries/regions, efforts which can 588 
impact the design of diagnostic tools or resistance management strategies. For example, the 589 
CYP6M2 in An. gambiae (EDI et al. 2014) and the CYP6Z1 (IBRAHIM et al. 2016a) in An. 590 
funestus have been shown to confer cross-resistance between pyrethroids and carbamates, so 591 
their significant over-expression in a population should prevent using carbamates as 592 
alternative to pyrethroids in an IRS campaign. 593 
2-The cytochrome P450 CYP9J11 is a common African pyrethroid resistance gene 594 
If significant differences are observed between regions, there are also similarities with 595 
common genes observed across the continent such as the P450 CYP9J11 which was over-596 
expressed in all three regions assessed here. However, because of its moderate level of 597 
expression, CYP9J11 may not be the primary resistance gene. Nevertheless, its significant 598 
catalytic efficiency in metabolising pyrethroid means it cannot be disregarded. CYP9J11 is 599 
the ortholog of CYP9J5 in An. gambiae which was recently shown to also metabolise 600 
pyrethroids and pyriproxyfen, and to be over-expressed Africa-wide in An. gambiae field 601 
populations from West (TOE et al. 2015), Central (FOSSOG TENE et al. 2013) and East Africa 602 
(NKYA et al. 2014) suggesting that this gene could be important in providing protection to a 603 
wide range of xenobiotics in malaria vectors. CYP9J11 is also located on the 3L chromosome 604 
where the rp3 (resistance to pyrethroid 3) QTL had previously been detected suggesting that it 605 
could be the main gene behind rp3 (WONDJI et al. 2005; WONDJI et al. 2007; WONDJI et al. 606 
2009). In addition to the ability to metabolize pyrethroids and confer resistance to An. 607 
funestus, CYP9J11 as previously shown for CYP6Z1 (IBRAHIM et al. 2016a) is a cross-608 
resistance gene, able to metabolize non-pyrethroid insecticides used in public health using 609 
non-canonical Michaelis-Menten kinetic mechanisms. Various P450s exhibit functional 610 
allostery using distributive catalysis to minimize toxicological effects of substrates (ATKINS et 611 
al. 2002), for example  the promiscuous CYP3A4 (WANG et al. 2000), CYP2C9 (TRACY et al. 612 
2002) and the recently characterized An. funestus CYP6Z1 (IBRAHIM et al. 2016a). At low 613 
substrate concentrations, the slower substrate turnover afforded by cooperative CYPs 614 
compared with Michaelis-Menten enzymes can be a significant toxicological advantage, when 615 
toxic thresholds exist (ATKINS et al. 2002). Possibly, bendiocarb is too ‘toxic’ for CYP9J11 616 
even though it can metabolise it and this is why the P450 employ distributive catalysis to 617 
effect its catalysis like the case of An. funestus CYP6Z1 (IBRAHIM et al. 2016a).  618 
3-Allelic variation of the glutathione S-transferase GSTe2 impacts pyrethroid 619 
resistance 620 
The significant over-expression of GSTe2 in Benin in pyrethroid resistant mosquitoes 621 
(as seen by the FC> 2 in R-C comparing permethrin resistant to control not exposed 622 
mosquitoes from Pahou) suggested that this gene could be involved in permethrin resistance. 623 
The significant lower mortality observed in transgenic Drosophila flies expressing the 624 
resistant 119F allele compared to those expressing the susceptible L119 allele supports the 625 
key role that allelic variation in this gene plays beside its over-transcription. As previously 626 
shown for DDT resistance it is likely that the 119F also enlarging the GSTe2 binding cavity 627 
to facilitate access of pyrethroid and allow either sequestration as suggested for glutathione S-628 
transferase action on pyrethroids (VONTAS et al. 2005) or a direct metabolism as established 629 
by  (RIVERON et al. 2014a). The ability of the transgenic expression in Drosophila flies to 630 
establish the phenotypic impact of the allelic variation of GSTe2 due to a single amino acid 631 
change highlights the robustness of this approach in functionally characterizing the role of 632 
candidate resistance genes in conferring resistance to insecticide. This shows that 633 
experimental results from transgenic Drosophila are very relevant to the phenotype obtained 634 
in mosquitoes while providing the advantage that studies in Drosophila could be easily scaled 635 
up to hundreds of genes at lower amount of work, cost and space for storage of transgenic 636 
lines. Allelic variation was also recently shown to play an important role in the pyrethroid 637 
resistance conferred by the duplicated P450s CYP6P9a and CYP6P9b in southern African 638 
populations of An. funestus (IBRAHIM et al. 2015b) suggesting that beside over-transcription 639 
of detoxification genes, amino acid changes in coding regions could also play a major role. 640 
Such cases will facilitate the design of DNA-based diagnostic tools to detect metabolic 641 
resistance in field populations as done already for L119F-GSTe2 mutation (RIVERON et al. 642 
2014a). 643 
Conclusion 644 
The comparative transcription analysis performed in this study between various 645 
African regions highlights that although metabolic resistance is the common driving 646 
mechanism of pyrethroid resistance in An. funestus populations, there are significant special 647 
variations on the main genes associated with it, which could impact patterns of cross–648 
resistance and resistance management strategies. The impact of many genes conferring 649 
resistance and cross-resistance to multiple resistant populations of An. funestus in sub-650 
Saharan African is a challenge to resistance management. This phenomenon makes the 651 
resistance highly heterogeneous and complex making the design of appropriate diagnostic 652 
tools operationally challenging. There is an overwhelming need for newer classes of 653 
insecticides that are safe but potent enough to control mosquito vectors of malaria and other 654 
diseases effectively. But caution must be exercised because of the presence of a number of 655 
detoxification enzymes that can confer cross-resistance and a new insecticide may already be 656 
doomed before being deployed if resistance genes can already metabolize it.   657 
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890 
Figure legends 891 
Figure 1: Transcription profile of pyrethroid resistance across Benin, Uganda and 892 
Malawi: A) Venn diagram summarising the number of probes differentially expressed in each 893 
and between comparisons in Uganda and (B) in Benin at fold-change (FC)>2 and P<0.05 in 894 
R-S, C-S and R-C comparisons as well as the commonly expressed probes. C) Venn-diagram 895 
of the comparison between Malawi, Uganda and Benin for the R-S comparison only. D) qRT-896 
PCR expression of key resistance genes in the 3 countries when comparing the permethrin 897 
resistant mosquitoes to the FANG susceptible (R-S. 898 
Figure 2: Genetic diversity pattern of CYP9J11 in East (Uganda; UG) and southern 899 
[Malawi (MAL) and Zambia (ZB)] Africa. A) Maximum likelihood tree of CYP9J11 from 900 
the cDNA haplotypes of the full-length 1644bp sequence. B) Genetic distances between 901 
African populations (Nst estimates) between the 3 countries. 902 
Figure 3: Functional validation of the role of CYP9J11 P450 gene in 903 
carbamate/pyrethroid resistance. (A) Percentage depletion of 20µM carbamate and 904 
pyrethroid insecticides with CYP9J11. Results are an average of three replicates (n = 3) 905 
compared with negative control. * and ** Significantly different from negative control (-906 
NADPH) at p<0.05 and p<0.01 respectively. B) Polar metabolites with short retention time 907 
eluted at the beginning of chromatogram of CYP9J11 metabolism of bendiocarb (NADPH+). 908 
A third putative metabolite of bendiocarb metabolism eluted at 18.045 minutes. C) 909 
Chromatogram of NADPH- incubation tubes devoid of polar metabolites with short retention 910 
indicating no metabolism of bendiocarb in the absence of NADPH regeneration agent. D) and 911 
E) Michaelis-Menten plot of CYP9J11 mediated metabolism of permethrin and deltamethrin 912 
respectively. Results are an average of three replicates (n = 3) compared with negative 913 
control; (F) Allosteric sigmoidal curve of CYP9J11 metabolism of bendiocarb. Results are 914 
average of three replicates (n = 3) compared with negative control. Khalf = KM. h =  2.29.  915 
 916 
Figure 4: Functional validation of the role candidate resistance genes using transgenic 917 
expression in flies: A) results of bioassay analysis of transgenic flies over-expressing 918 
CYP9J11 Act5C-CYP9J11 vs control flies for deltamethrin. (B) The same bioassays with 919 
permethrin. C) Functional validation of the role of allelic variation at the GSTe2 genes on the 920 
resistance phenotype using transgenic expression in flies through a comparative transgenic 921 
analysis of the 119F and L119-GSTe2 alleles using bioassay tests on transgenic Act5C-922 
GSTe2-119F (GSTe2-Benin) and Act5C-GSTe2-L119 (GSTe2-Malawi) and flies (Exp-923 
GSTe2), control strains [two parental (UAS-GSTe2 and GAL4-Actin) and F1 progeny that do 924 
not express the GSTe2 transgene (Cont-NO)]. D) The same bioassays with permethrin. E) 925 
Relative expression of the transgene GSTe2 alleles in the transgenic D. melanogaster strain 926 
(Act5C-GSTe2-MAL and Act5C-GSTe2-BN) and the control sample with no GSTe2 927 
expression (Cont Act5c-NO). Data shown as mean ±S.E.M. significantly different: * p<0.05, 928 
** p<0.01 and *** p<0.001. 929 
 930 
Figure 5: Molecular phylogenetic analysis of CYP6P9a (A) and CYP6P9b (B) in Uganda 931 
(UG) for both permethrin resistant and susceptible mosquitoes in comparison to Malawi 932 
(Mal) using the Maximum Likelihood method. The evolutionary history was inferred by 933 
using the Maximum Likelihood method based on the Tamura 3-parameter model. The tree 934 
with the highest log likelihood is shown. Initial tree(s) for the heuristic search were obtained 935 
by applying the Neighbor-Joining method to a matrix of pairwise distances estimated using 936 
the Maximum Composite Likelihood (MCL) approach. The tree is drawn to scale, with 937 
branch lengths measured in the number of substitutions per site. The analysis involved 46 938 
(CYP6P9a) and 50 (CYP6P9b) nucleotide sequences. All positions containing gaps and 939 
missing data were eliminated. There were a total of 1990 (CYP6P9a) and1757 (CYP6P9b) 940 
positions in the final dataset. Evolutionary analyses were conducted in MEGA6. 941 
 942 
Table 1: List of top detoxification genes significantly over-expressed in pyrethroid resistant An. funestus in Uganda for all comparisons  
Probes Transcripts An. gambiae ID 
 
R-C R-S C-S Description 
CUST_12777_PI426302897 Afun012777 CYP4C27 AGAP009246-PA 3.6 10.3 6.8 cytochrome p450 
CUST_8293_PI426302897 Afun008293 AGAP008291-PA  187.8 83.0 trypsin-related protease 
CUST_7663_PI426302897 Afun007663 (CYP6M7) AGAP008213-PA  70.1 24.0 cytochrome p450  
CUST_13921_PI426302897 Afun013921 AGAP006709-PA  64.4 49.5 chymotrypsin 1 
CUST_500_PI426302897 Afun000500 NA 
 
 27.1 23.0 glycogenin 
CUST_9227_PI426302897 Afun009227 AGAP008141-PA  22.8 21.2 argininosuccinate lyase 
CUST_7769_PI426302897 Afun007769 (CYP9K1) AGAP000818-PA  21.5 16.1 cytochrome p450  
CUST_15331_PI426302897 Afun015331 (CYP307A1) AGAP001039-PB  16.6 3.9 cytochrome p450  
CUST_11042_PI426302897 Afun011042 AGAP003321-PA  13.3 8.1 glycine dehydrogenase 
CUST_13870_PI426302897 Afun013870 AGAP012697-PA  11.9 14.8 sulfotransferase 
CUST_295_PI406199798 AGAP000177-RA AGAP000177-RA  10.5 8.0 cuticle protein 7 
CUST_4223_PI426302897 Afun004223 (CYP4H17) AGAP008358-PA  10.1 7.5 cytochrome p450 
CUST_15523_PI426302897 Afun015523 AGAP010581-PA  8.1 5.7 abc transporter 
CUST_4631_PI406199798 AGAP005698-RA AGAP005698-RA  7.6 3.5 cuticular protein 4  
CUST_1458_PI406199769 combined_c738 
  
 6.7 4.9 short-chain dehydrogenase 
CUST_13481_PI426302897 Afun013481 (GSTe1) AGAP009195-PA  6.6 5.6 glutathione-s-transferase 
CUST_3246_PI426302897 Afun003246 AGAP006220-PA  6.5 4.5 aldehyde oxidase 
CUST_8354_PI426302897 Afun008354 (GSTD3) AGAP004382-PA  6.5 5.1 glutathione transferase 
CUST_12343_PI426302897 Afun012343 (CYP4H17) AGAP008358-PA  6.0 4.4 cytochrome p450 4d1 
CUST_11963_PI426302897 Afun011963 AGAP006220-PA  5.7 4.0 aldehyde oxidase 
CUST_11037_PI426302897 Afun011037 AGAP003581-PA  5.7 8.0 alcohol dehydrogenase 
CUST_376_PI406199788 gb-CYP4H25 
  
 5.4 5.3 cytochrome p450 
CUST_12197_PI426302897 Afun012197 (CYP304B1) AGAP003066-PA  5.2 3.3 cytochrome p450 
CUST_7127_PI426302897 Afun007127 (CYP4C36) AGAP009241-PA  5.2 2.6 cytochrome p450 
CUST_6930_PI426302897 Afun006930 (CYP6M2) AGAP008212-PA  5.1 5.3 cytochrome p450 
CUST_7861_PI426302897 Afun007861 (CYP6Z1) AGAP008219-PA  4.8 2.5 cytochrome p450 
CUST_10949_PI426302897 Afun010949 AGAP010887-PA  4.6 7.4 cuticular protein rr-1 family  
CUST_7696_PI406199798 AGAP008141-RA AGAP008141-RA  4.6 2.2 argininosuccinate lyase 
CUST_3731_PI406199772 CD577517.1 
  
 4.2 4.7 cuticle protein 
CUST_7369_PI426302897 Afun007369 (CYP6P9a) AGAP002865-PA  4.2 3.0 cytochrome p450 
CUST_13871_PI426302897 Afun013871 AGAP012697-PA  4.1 2.3 sulfotransferase 
CUST_13273_PI406199769 combined_c6791 (CYP9J11) AGAP012296-PA  4.1 3.6 cytochrome p450 
CUST_12461_PI426302897 Afun012461 AGAP000288-PA  4.1 6.8 alcohol dehydrogenase 
CUST_7722_PI426302897 Afun007722 AGAP009850-PA  4.0 3.6 abc transporter 
CUST_10360_PI426302897 Afun010360 AGAP006222-PA  4.0 3.2 UDP glucosyl transferases 
CUST_9866_PI426302897 Afun009866 (GSTe5) AGAP009192-PA  3.9 2.7 glutathione-s-transferase 
CUST_9492_PI426302897 Afun009492 AGAP001722-PA  3.8 8.8 carboxylesterase 
CUST_7469_PI426302897 Afun007469 (CYP9J11) AGAP012296-PA  3.8 3.0 cytochrome p450 
CUST_15244_PI426302897 Afun015244 AGAP000820-PA  3.7 5.9 cuticular protein rr-1 family 
CUST_10836_PI426302897 Afun010836 AGAP006228-PA  3.4 2.3 esterase b1 
CUST_484_PI406199788 gb-CYP9J3 
  
 3.3 2.1 cytochrome p450 
CUST_12666_PI426302897 Afun012666 (CYP315A1) AGAP002429-PA  3.2 3.7 cytochrome p450 
CUST_405_PI406199788 gb-CYP6AD1 
  
 3.2 2.0 cytochrome p450 
CUST_9027_PI426302897 Afun009027 AGAP009463-PA  3.1 2.1 abc transporter 
CUST_9335_PI426302897 Afun009335 AGAP003343-PA  3.1 2.8 cytochrome p450 
CUST_720_PI406199788 gb-PX4B 
  
 3.1 2.8 oxidase peroxidase 
CUST_10630_PI426302897 Afun010630 (CYP6P5) AGAP002866-PA  3.1 6.3 cytochrome p450 
CUST_45_PI426302897 Afun000045 (GSTe2) AGAP009194-PA  2.9 2.1 glutathione-s-transferase gst 
CUST_10994_PI426302897 Afun010994 (CYP6P4) AGAP002867-PA  2.8 3.2 cytochrome p450 
CUST_30_PI426302915 CYP6Z3 
  
 2.8 2.4 cytochrome p450 
CUST_3315_PI406199769 combined_c1675 
  
 2.7 2.6 UDP glucosyl transferases 
CUST_8909_PI426302897 Afun008909 (CYP4K2) AGAP002416-PA  2.7 3.0 cytochrome p450 
CUST_35_PI406199775 COEAE6O AGAP002863-PA  2.6 3.1 carboxylesterase 
CUST_7499_PI426302897 Afun007499 (GSTD1-5) AGAP004164-PA  2.5 2.1 glutathione transferase 
CUST_9584_PI426302897 Afun009584 (CYP6M4) AGAP008214-PA  2.3 3.2 cytochrome p450 
CUST_3394_PI426302897 Afun003394 (CYP325A1) AGAP000284-PA  2.1 2.1 cytochrome p450 
Table 2: List of top detoxification genes significantly over-expressed in pyrethroid resistant An. 
funestus in Benin for all comparisons 
Probes Transcript   C-S R-C R-S Description 
CUST_1822_PI406199769 combined_c920  11.9 2.6 35.5 glutathione-s-transferase gst 
CUST_1822_PI406199769 combined_c920  8.8 2.0 25.2 glutathione-s-transferase gst 
CUST_30_PI406199775 CYP6P9b  3.9  2.9 cytochrome p450 
CUST_25_PI406199775 CYP6P9a  6.4  2.8 cytochrome p450 
CUST_1616_PI406199772 EE589516.1  2.3  2.6 d7-related 1 protein 
CUST_8241_PI406199769 combined_c4173  11.6  9.5 glycoprotein 93 
CUST_1964_PI406199772 CD664227.1 
 
 2.4 2.0 alcohol dehydrogenase 
CUST_2550_PI406199769 combined_c1287  2.4 2.3 aldehyde dehydrogenase 
CUST_3110_PI406199772 CD577844.1 
 
 4.8 4.7 cuticle protein 
CUST_13273_PI406199769 
combined_c6791 
(CYP9J11) 
 
2.6 2.5 cytochrome p450 
CUST_13272_PI406199769 
combined_c6791 
(CYP9J11) 
 
2.8 2.6 cytochrome p450 
CUST_604_PI406199772 EE589610.1 
 
 3.2 2.8 d7-related 1 protein 
CUST_1090_PI406199798 AGAP000881-RA    2.1 aldehyde dehydrogenase 
CUST_2068_PI406199798 AGAP002182-RA    2.7 ABC transporter 
CUST_4410_PI406201128 AGAP001777-RA    3.0 ABC transporter 
CUST_3109_PI406199772 CD577844.1    5.0 cuticle protein 
CUST_4919_PI406199772 BU038983    4.7 cuticle protein 
CUST_3398_PI406199772 CD577693.1    5.2 cuticle protein 
CUST_48_PI406199775 CYP6Z3    2.5 cytochrome p450 
CUST_10_PI406199775 CYP6P1    2.1 cytochrome p450 
CUST_43_PI406199775 CYP6Z1    2.4 cytochrome p450 
CUST_45_PI406199775 CYP6Z1    3.3 cytochrome p450 
CUST_27_PI406199775 CYP6P9a    2.6 cytochrome p450 
CUST_44_PI406199775 CYP6Z1    3.5 cytochrome p450 
CUST_717_PI406199772 EE589504.1    9.0 d7-related 1 protein 
CUST_359_PI406199772 EE589855.1    9.1 d7-related 1 protein 
CUST_1687_PI406199772 EE589439.1    8.2 d7-related 1 protein 
CUST_959_PI406199772 EE589285.1    3.6 gsg6 salivary protein 
CUST_379_PI406199772 EE589823.1    2.2 gsg7 salivary protein 
CUST_5934_PI406199769 combined_c3002    2.4 superoxide dismutase 
CUST_21644_PI406201128 AGAP006867-RA  5.2   
adult-specific cuticular protein 
acp-20 
CUST_120_PI406199788 gb-COEAE1G  5.1   alpha-esterase 
CUST_21714_PI406201128 AGAP010906-RA  3.6   cuticle protein 
CUST_2401_PI406199769 combined_c1211  2.1   
glucosyl glucuronosyl 
transferases 
CUST_178_PI406199772 EE590018.1  2.2   gsg7 salivary protein 
CUST_6_PI406199775 CYP6AA1   2.0  cytochrome p450 
CUST_11_PI406199775 CYP6P1   2.5  cytochrome p450 
CUST_24_PI406199775 CYP6P5   2.1  cytochrome p450 
CUST_26_PI406199775 CYP6P9a   2.2  cytochrome p450 
CUST_1682_PI406199772 EE589442.1   2.5  d7 protein 
CUST_1182_PI406199772 EE589982.1   2.5  d7-related 1 protein 
CUST_892_PI406199772 EE589340.1   2.8  d7-related 3 protein 
CUST_3946_PI406199772 CD577403.1   3.2  glutathione s-transferase 
CUST_14377_PI406199769 combined_c7513   2.6  glutathione transferase 
 
Table 3: Detoxification genes commonly up-regulated in Uganda (UG), Malawi (MAL) and Benin (BN) countries 
Probe Name An. funestus ID An. gambiae ID UG MAL BN Description 
CUST_8293_PI426302897 Afun008293 AGAP008291-PA 83.0 32.5 74.4 trypsin-related protease 
CUST_7663_PI426302897 Afun007663 (CYP6M7) AGAP008213-PA 24.0 12.5 131.9 cytochrome p450 
CUST_500_PI426302897 Afun000500 
 
23.0 8.8 17.1 glycogenin 
CUST_9227_PI426302897 Afun009227 AGAP008141-PA 21.2 66.3 29.2 argininosuccinate lyase 
CUST_8887_PI426302897 Afun008887 AGAP011997-PA 17.6 8.5 7.3 nucleotide binding protein 2 (nbp 2) 
CUST_7769_PI426302897 Afun007769 (CYP9K1) AGAP000818-PA 16.1 2.4 6.2 cytochrome p450 
CUST_1392_PI426302897 Afun001392 
 
10.7 8.8 6.0 glycine dehydrogenase 
CUST_11042_PI426302897 Afun011042 AGAP003321-PA 8.1 18.5 6.4 glycine dehydrogenase 
CUST_4223_PI426302897 Afun004223 (CYP4H17) AGAP008358-PA 7.5 6.8 9.5 cytochrome p450 
CUST_10949_PI426302897 Afun010949 AGAP010887-PA 7.4 3.0 4.2 cuticular protein rr-1 family 
CUST_1459_PI406199769 combined_c738 
 
7.3 6.4 10.9 short-chain dehydrogenase 
CUST_6930_PI426302897 Afun006930 (CYP6M2) AGAP008212-PA 5.3 4.3 5.0 cytochrome p450 
CUST_3246_PI426302897 Afun003246 AGAP006220-PA 4.5 3.8 4.2 aldehyde oxidase 
CUST_1563_PI406199772 EE589574.1 
 
4.4 2.1 2.8 d7-related 1 protein 
CUST_12343_PI426302897 Afun012343 (CYP4H17) AGAP008358-PA 4.4 2.9 4.2 cytochrome p450 4d1 
CUST_8347_PI426302897 Afun008347 AGAP009828-PA 3.9 4.2 5.0 chymotrypsin 1 
CUST_9522_PI426302897 Afun009522 (CYP9J13) AGAP012292-PA 3.5 4.5 2.8 cytochrome p450 
CUST_1710_PI406199772 EE589412.1 
 
3.3 2.2 2.6 d7-related 1 protein 
CUST_12197_PI426302897 Afun012197 (CYP304B1) AGAP003066-PA 3.3 2.8 4.1 cytochrome p450 
CUST_10360_PI426302897 Afun010360 AGAP006222-PA 3.2 2.0 4.8 glucosyl glucuronosyl transferases 
CUST_9584_PI426302897 Afun009584 (CYP6M4) AGAP008214-PA 3.2 3.2 3.3 cytochrome p450  
CUST_27_PI426302915 CYP6Z1 
 
3.1 2.5 2.3 cytochrome p450 
CUST_198_PI406199772 EE590001.1 
 
3.0 2.1 3.1 d7-related 1 protein 
CUST_7369_PI426302897 
Afun007369 (CYP6P9a-
like) AGAP002865-PA 3.0 2.5 4.4 cytochrome p450 
CUST_7469_PI426302897 Afun007469 (CYP9J11) AGAP012296-PA 3.0 3.1 2.7 cytochrome p450 
CUST_3109_PI406199772 CD577844.1 
 
2.9 2.5 2.4 cuticle protein 
CUST_9335_PI426302897 Afun009335 AGAP003343-PA 2.8 2.7 2.7 cytochrome p450 
CUST_2473_PI426302897 Afun002473 AGAP000553-PA 2.5 4.5 2.5 atp-binding-cassette protein 
CUST_7861_PI426302897 Afun007861  AGAP008219-PA 2.5 3.1 2.2 cytochrome p450 
CUST_1097_PI406199769 combined_c557 
 
2.5 6.4 5.1 trypsin 
CUST_10_PI426302915 CYP6M4.seq 
 
2.4 2.6 3.2 cytochrome p450 
CUST_798_PI426302897 Afun000798 (CYP6M2) AGAP008212-PA 2.1 2.5 2.6 cytochrome p450 
 
 
 





